Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.25
Bid: 27.00
Ask: 27.50
Change: 0.00 (0.00%)
Spread: 0.50 (1.852%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 27.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Bank of Cyprus swings profit; Sareum loss widens

Mon, 21st Feb 2022 18:13

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Bank of Cyprus Holdings PLC - Nicosia-based lender - Reports turnover of EUR755.2 million for 2021, down from EUR765.1 million in 2020. Despite this, swings to pretax profit of EUR36.1 million from loss of EUR166.9 million. Is helped by sharply reduced credit losses to cover credit risk on loans and advances to customers, booking expense of EUR40.3 million in 2021 versus charge of EUR275.1 million in 2020. "2021 saw a strong recovery in the Cypriot economy after a period of pandemic-related disruption, providing an improved backdrop against which the Bank performed well. During the year we continued to support the country's return to growth, extending EUR1.8 bn of new loans, an increase of a third on the prior year and steadily recovering towards pre-pandemic levels," says Chief Executive Panicos Nicolaou. Looking ahead, now targets return on tangible equity in medium-term in excess of 10%, "providing the foundations for a return of dividend distributions, subject to performance and relevant approvals."

----------

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Pretax loss for six months to December 31 widens to GBP1.0 million from GBP610,000 year-on-year, with no revenue generated in either period. Says it is looking to 2022 with optimism and expects to report on continued progress both with its proprietary programmes, in particular the advancement of SDC-1801 into clinical trials, and with partnered asset, SRA737, should Sierra advance its development. "The board and management also continue to employ rigorous capital allocation in the development of internal assets and the overall business, with a clear focus on generating value for shareholders," firm says.

----------

Sylvania Platinum Ltd - Bermuda-based platinum group metals producer - Revenue for six months to end of December falls to USD69.1 million from USD84.9 million, while pretax profit drops to USD34.9 million from USD57.4 million. Sylvania Dump Operations delivered 32,376 4E PGM ounces, down from 36,335 ounces a year ago. Notes lower than planned run of mine and current arising PGM feed grades at the Western operations affected production, as well as temporary suspension of operations at Lesedi extended through the first quarter and, subsequent to start-up, the plant incurred further downtime related to general water shortages at the Western operations during the second quarter. Declares windfall dividend of 2.25 pence, to be paid in April. "Based on the progress that we are making with the Lesedi MF2, which we plan to commission in March, as well as the provisional results from targeted sampling campaigns and investigations to evaluate potential alternative feed sources to mitigate current low ROM feed grades at Mooinooi, we are expecting a stronger production performance during HY2 FY2022," says Chief Executive Jaco Prinsloo.

----------

Graft Polymer (UK) PLC - Slovenia-based polymer modification and drug delivery systems - Expects an increase in commercial orders following successful trials. To meet demand, firm has moved to a two-shift operation at its Slovenia production facility to ensure order fulfilment. Full production capacity at the existing facilities is results in an output of 4,000 tonnes of product per year. "This is in line with the strategy of investing in additional equipment at its facility to increase the production capabilities as set out in the IPO prospectus. These investments will allow the Company to increase its current production output to 6,000 tonnes per annum," firm says. Adds that Slovenian Intellectual Property Office has awarded company four new patents.

----------

Cellular Goods PLC - London-based cannabinoid product company - After strategy review, says it will exclusively focus on wellness products across its three market verticals, being skincare, supplements and recovery. Says initial sales of inaugural products have been below internal forecasts due to "market challenges". "The company has identified various factors that negatively impacted sales, including a policy decision by some of the world's largest social media companies. Google, and Meta's platforms Facebook and Instagram, prohibit advertising cannabis-derived products, which has prevented the company's products from being promoted there," firm says. Has made changes to media mix for its upcoming marketing campaign. Says it has accelerated retail partnerships and has launched Look Better range on Amazon Marketplace.

----------

Immotion Group PLC - Manchester, England-based virtual reality entertainment company - Says second half revenue was around GBP6.6 million, more than double the GBP2.8 million in the first half of the year. Second half operating cash inflow was strong, with year-end cash on hand of GBP1.1 million, almost double the GBP600,000 at the half year. "Overall, we feel we have made good progress across the company and are looking forward with renewed confidence," says Chief Executive Martin Higginson. Adds that it has got contract extension and expansion of capacity at Shark Reef Aquarium, inside Mandalay Bay Resort & Casino, Las Vegas, currently the group's largest installation. This will see the theatre capacity increase to 48 seats from its current 36 seats, and the contract will be extended by a further 12 months through to January 31, 2024. Says that in addition, capacity at another two of its strongest performing sites has been "significantly expanded".

----------

Allied Minds PLC - Boston, Massachusetts-based intellectual property commercialisation company - Says portfolio company Federated Wireless has secured USD58 million in Series D funding at a pre new-money valuation of USD230 million. Allied Minds participates in fundraise, alongside an affiliate of Cerberus Capital Management LP and GIC, Singapore's sovereign wealth fund. "We're proud of the achievements made by Federated Wireless, which have been recognised by investors in this well-backed funding round," says Chair Harry Rein. Adds that Mark Pritchard, founder and former executive chair of Allied Minds and a 5.5% shareholder, has been appointed as a consultant to the board.

----------

BiVictriX Therapeutics PLC - Macclesfield, England-based drug development company specialising in cancer treatments - Files four new patent applications in the UK related to several novel cancer-specific antigen pairs or "fingerprints" across a range of oncology indications. These applications focus on three novel cancer-specific antigen fingerprints that have been identified by the company and can support the development of a pipeline of highly selective cancer therapeutics utilising the company's Bi-Cygni approach. "These filings are the next step in the company's strategy to broaden its patent portfolio both in the UK and internationally," it says.

----------

Polar Capital Global Financials Trust PLC - London-based financial investor - Plans to raise additional funds through share issue as interest in company "remains high" and appetite for shares "has not diminished". To issue new shares at a placing price to be published on the day following the closing date of the placing. "The directors and Polar Capital LLP continue to believe that the company is well positioned to benefit from higher interest rates, rising inflation expectations and stronger economic growth given the significant exposure of the portfolio to banks in particular," firm says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
13 Sep 2022 08:13

CORRECT: Sareum notes US FDA approval of Bristol-Myers's Sotyktu

(Correcting that Bristol-Myers gained US FDA approval, not Sareum.)

Read more
12 Sep 2022 12:27

Sareum receives US US Food & Drug Administration approval for Sotyktu

(Alliance News) - Sareum Holdings PLC on Monday said the US Food & Drug Administration has approved Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor.

Read more
4 Jul 2022 11:23

IN BRIEF: Sareum notes updated payment terms after GSK buy of SRA737

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Notes that GSK PLC has completed its acquisition of Sierra Oncology Inc, the licence holder of SRA737, for USD1.9 billion. SRA737 was discovered and initially developed by scientists at the Institute of Cancer Research in collaboration with Sareum.

Read more
10 Jun 2022 11:19

Midatech Chair Rolf Stahel retires; Stephen Parker named as successor

(Alliance News) - Midatech Pharma PLC on Friday said that Chair Rolf Stahel plans to leave the board on June 20, and it named Stephen Parker as his successor.

Read more
13 Apr 2022 21:59

TRADING UPDATES: Sureserve gets new CFO; Sareum notes GSK buys Sierra

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Apr 2022 20:51

TRADING UPDATES: Pod Point wins BMW deal; Lamprell seals contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
16 Mar 2022 14:21

Sareum progresses Covid-19 and autoimmune treatment candidate

(Sharecast News) - Specialist drug developer Sareum Holdings updated the market on the development of its 'SDC-1801' - a potential Covid-19 and autoimmune disease treatment - towards first-in-human trials on Wednesday.

Read more
21 Feb 2022 15:55

UK shareholder meetings calendar - next 7 days

Tuesday 22 February 
Aberdeen Diversified Income & Growth Trust PLCAGM
Image Scan Holdings PLCAGM
Montanaro European Smaller Cos Trust PLCGM share issue
Wednesday 23 February 
Blencowe Resources PLCAGM
Gooch & Housego PLCAGM
Income & Growth VCT PLCGM re share subscription
Mobeus Income & Growth 2 VCT PLCGM re share subscription
Mobeus Income & Growth 4 VCT PLCGM re share subscription
Mobeus Income & Growth VCT PLCGM re share subscription
RWS Holdings PLCAGM
Tharisa PLCAGM
Titon Holdings PLCAGM
Thursday 24 February 
Bankers Investment Trust PLCAGM
IntegraFin Holdings PLCAGM
Victorian Plumbing Group PLCAGM
Friday 25 February 
Caledonian Trust PLCAGM
GRIT Investment Trust PLCAGM
Henderson Diversified Income Trust PLCGM re investment policy
On the Beach Group PLCAGM
Ruffer Investment Co LtdEGM re authority to issue shares
Monday 28 February 
Alternative Liquidity Fund LtdEGM
Ramsdens Holdings PLCAGM
Sareum Holdings PLCEGM re share consolidation
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
4 Feb 2022 14:37

IN BRIEF: Drug maker Sareum plans 50-into-1 share consolidation

IN BRIEF: Drug maker Sareum plans 50-into-1 share consolidation

Read more
17 Dec 2021 19:28

IN BRIEF: Sareum raises GBP1.6 million to advance inhibitor programmes

IN BRIEF: Sareum raises GBP1.6 million to advance inhibitor programmes

Read more
9 Dec 2021 14:43

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
23 Nov 2021 16:21

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

Read more
25 Oct 2021 08:48

Sareum full-year loss widens on research & development costs

Sareum full-year loss widens on research & development costs

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.